Immutep Halts Phase III NSCLC Trial After Futility Analysis
Event summary
- Immutep's Phase III TACTI-004 trial for eftilagimod alfa in first-line NSCLC discontinued due to futility analysis.
- IDMC recommended discontinuation after reviewing interim safety and efficacy data.
- Trial was evaluating efti in combination with Merck's KEYTRUDA® and chemotherapy.
- Immutep anticipates extended cash runway beyond previously guided Q2 2027.
- Company will conduct comprehensive data review to determine next steps for the program.
The big picture
The discontinuation of TACTI-004 is a significant setback for Immutep's lead asset, eftilagimod alfa, in NSCLC. This decision comes despite efti's promising performance in other trials, highlighting the unpredictable nature of oncology drug development. The extended cash runway provides some breathing room, but the company must now demonstrate its ability to pivot and deliver value through its other programs. The broader immunotherapy space continues to face challenges in combining therapies to achieve meaningful clinical outcomes.
What we're watching
- Pipeline Strategy
- How Immutep will reprioritize its pipeline following this setback.
- Financial Flexibility
- The pace at which Immutep burns through its extended cash runway.
- Regulatory Engagement
- Whether Immutep can leverage its Fast Track designations for other indications.
Related topics